[Peptide CY11 conjugated polyethylenimine-beta-cyclodextrin for gene delivery]

Area of Science:

• Biomaterials Science
• Gene Therapy
• Nanotechnology

Context:

• Non-viral gene delivery systems are crucial for therapeutic applications, aiming to overcome the limitations of viral vectors.
• Developing efficient and safe gene delivery vectors remains a significant challenge in molecular medicine.
• Polyethylenimine (PEI) and cyclodextrins are known for their gene delivery capabilities, but often face issues with toxicity or efficiency.

Purpose:

• To synthesize and characterize a novel non-viral gene delivery vector, CY11-PEI-beta-CyD.
• To evaluate the DNA condensation ability, cytotoxicity, and gene transfection efficiency of the developed vector.
• To compare the performance of CY11-PEI-beta-CyD with a standard non-viral vector, PEI 25 kDa.

Summary:

• The novel vector CY11-PEI-beta-CyD was successfully synthesized by conjugating CY11 peptide to polyethylenimine-beta-cyclodextrin using SPDP cross-linker, confirmed by (1)H NMR and TGA.
• The vector demonstrated effective DNA condensation at an N/P ratio of 4 and exhibited low cytotoxicity up to 160 µg/mL.
• Transfection efficiency was found to be 17-fold higher than PEI 25 kDa at an N/P ratio of 20 in COS-7, HeLa, and B16 cells.

Impact:

• The CY11-PEI-beta-CyD vector presents a promising alternative to existing gene delivery methods.
• Its low cytotoxicity and high transfection efficiency suggest potential for clinical applications in gene therapy.
• This development contributes to the advancement of safer and more effective non-viral gene delivery strategies.